Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Yescarta One Of Few Gilead Bright Spots, And Now It Has A Competing CAR-T

May 02 2018

• By Mandy Jackson

Hitting bigger business target

Related Content

Gilead/Kite Pricing For Yescarta Undercuts Novartis's CAR-T Kymriah

Oct 19 2017

Gilead Completes HCV Clinical Development With Vosevi Approval

Jul 18 2017

HIV Market Snapshot: Gilead's Biktarvy Set To Soar, But ViiV May Win In The End

Apr 18 2018

Gilead's Biktarvy Profile Rises As CHMP Backs Daily HIV Therapy

Apr 30 2018

EU CAR-T Race Tightens After Yescarta Reverts To Standard Review

Apr 23 2018

Gilead's R&D Leadership Change Is End Of Bischofberger Era

Mar 12 2018

Gilead's Biktarvy Approval Heightens HIV Competition With ViiV

Feb 07 2018

Novartis Beats CAR-T Competitors To The Pricing Punch With Kymriah Approval

Aug 31 2017

Gilead Makes Cell Therapy The Base Of Its Oncology Platform With Kite Buy

Aug 29 2017

HCV Sales Drive AbbVie's Great Quarter, But Gains Won't Last

Apr 27 2018

Related Companies

Gilead Sciences, Inc.

Novartis AG

Kite Pharma, Inc.

GSK plc

Pfizer Inc.

Shionogi & Co. Ltd.

ViiV Healthcare

AbbVie Inc.

Additional Topics

Sales & Earnings Business Strategies ImmunoOncology Companies Commercial BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window